Meridian Funds, managed by ArrowMark Partners, released its “Meridian Contrarian Fund” second quarter 2022 investor letter. A copy of the same can be downloaded here.
In last trading session, Talis Biomedical Corporation (NASDAQ:TLIS) saw 0.34 million shares changing hands with its beta currently measuring 0. Company’s recent per share price level of $4.66 trading at $0.06 or 1.30% at ring of the bell on the day assigns it a market valuation of $124.14M. That c